GW Pharmaceuticals
GW Pharmaceuticals was a UK-based biopharmaceutical company that developed Epidiolex, the first FDA-approved plant-derived CBD prescription drug for severe epilepsy forms including Dravet and Lennox-Gastaut syndromes, before being acquired by Jazz Pharmaceuticals for $7.2 billion in 2021.
- Company typePrivate
- Founded1998
- HeadquartersHiston, United Kingdom
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What GW Pharmaceuticals does
GW Pharmaceuticals plc was a United Kingdom-based biopharmaceutical company founded in 1998 and headquartered in Cambridge, UK. The company specialized in the discovery, development, and commercialization of novel cannabinoid-based prescription therapeutics, with its flagship product Epidiolex — the first FDA-approved plant-derived cannabidiol (CBD) prescription medication, indicated for severe forms of epilepsy including Dravet syndrome and Lennox-Gastaut syndrome following its 2018 regulatory approval. Underlying Epidiolex was proprietary expertise in pharmaceutical-grade CBD formulation, including standardized dosing, purity controls, and clinical validation that differentiate a regulated prescription drug from consumer CBD products.
The company monetized Epidiolex through traditional pharmaceutical distribution channels — specialty pharmacies, hospitals, and licensed healthcare providers — selling to patients with treatment-resistant severe epilepsy. Revenue mechanics were product-sale driven under an FDA-approved prescription label, with marketing executed through healthcare-provider engagement, medical conferences, and scientific publications. GW also extended its research into adjacent indications, notably Opioid Use Disorder in collaboration with Astellas Pharma and Opiant Pharmaceuticals, and supported next-generation CBD drug product development with partners such as dsm-firmenich (CBtru intermediate).
GW Pharmaceuticals was publicly traded on NASDAQ (ticker: GWPH) until its $7.2 billion acquisition by Jazz Pharmaceuticals in 2021, after which it has operated as a wholly-owned subsidiary of Jazz within its neuroscience and epilepsy franchise. At the time of acquisition the company had 1,001–5,000 employees and was led by founder Geoffrey Guy along with a bench including James Noble (Deputy Chairman), Douglas Snyder (CLO), Scott Giacobello (CFO), Volker Knappertz (CMO), Julian Gangolli (President of North America), and Adam George (UK Managing Director).
GW Pharmaceuticals firmographics
Firmographics- Name
- GW Pharmaceuticals
- Legal name
- GW Pharmaceuticals plc
- Website
- https://gwpharm.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Acquired
- Headcount range
- 1,001–5,000 employees
- Short description
- GW Pharmaceuticals was a UK-based biopharmaceutical company that developed Epidiolex, the first FDA-approved plant-derived CBD prescription drug for severe epilepsy forms including Dravet and Lennox-Gastaut syndromes, before being acquired by Jazz Pharmaceuticals for $7.2 billion in 2021.
- Ownership category
- akta.pro rank
GW Pharmaceuticals industry classification
Industry- Product category
- Cannabinoid Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where GW Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Histon
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
GW Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Product Sales: Sale of FDA-approved prescription medications, specifically Epidiolex for severe epilepsy treatment
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
GW Pharmaceuticals product offering
Product offeringCore offering
GW Pharmaceuticals develops and commercializes FDA-approved prescription medications derived from cannabinoids, with its primary product being Epidiolex, a pharmaceutical-grade CBD oral solution approved for the treatment of severe forms of epilepsy including Dravet syndrome and Lennox-Gastaut syndrome. The company also maintained a research pipeline exploring novel cannabinoid therapeutics for additional indications such as opioid use disorder.
Product overview
GW Pharmaceuticals was a pharmaceutical company specializing in the development and commercialization of cannabinoid-based prescription medicines. The company's primary product was Epidiolex, an FDA-approved CBD-based medication for severe epilepsy. GW Pharmaceuticals was acquired by Jazz Pharmaceuticals for $7.2 billion in 2021.
Differentiator
Problem solved
Functional benefit
Brands
- Epidiolex: FDA-approved CBD-based prescription medication for severe forms of epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome.
Products and services
- Epidiolex FDA-approved CBD-based prescription medication indicated for the treatment of severe forms of epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome. It is a pharmaceutical-grade oral solution of cannabidiol designed for patients with treatment-resistant severe epilepsies.
Quantifiable outcome
- FDA approval for treatment of Dravet syndrome and Lennox-Gastaut syndrome
Companies that use GW Pharmaceuticals
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
GW Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
GW Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- Jazz PharmaceuticalsflagshipJazz Pharmaceuticals acquired GW Pharmaceuticals for $7.2 billion in 2021, gaining Epidiolex, the FDA-approved CBD-based prescription medication for severe epilepsy forms. This acquisition significantly expanded Jazz's neuroscience portfolio and cannabis-based pharmaceutical capabilities.
- Astellas PharmacoreGW Pharmaceuticals is actively working on clinical trials for Opioid Use Disorder treatments alongside Astellas Pharma and Opiant Pharmaceuticals, as part of a robust pipeline of over 10 key pharmaceutical companies in this domain.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
GW Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Marinus Pharmaceuticals: Marinus developed Ztalmy (ganaxolone), an FDA-approved treatment for CDKL5 deficiency disorder, a rare developmental epilepsy. It is comparable as a small CNS specialty pharma focused specifically on rare/seizure disorders.
- UCB: UCB is a global biopharmaceutical company whose core neuroscience franchise includes epilepsy treatments (e.g., Briviact, Vimpat, Keppra). It is the closest direct peer given shared focus on branded prescription neurology/epilepsy drugs distributed via the same specialty pharmacy channels.
- Biohaven Pharmaceuticals: Biohaven is a CNS-focused biopharmaceutical company, originally spun out and later acquired by Pfizer, with branded neurology therapies distributed through specialty pharmacy — overlapping with GW's specialty CNS distribution model.
- SK Life Science: SK Life Science markets cenobamate (Xcopri) for focal-onset seizures in the US and operates in the branded prescription epilepsy space with comparable patient overlap to Epidiolex.
- Zogenix: Zogenix developed Fintepla (fenfluramine) for Dravet and Lennox-Gastaut syndromes — the same indications targeted by Epidiolex — making it the most direct patient-overlap competitor in severe pediatric epilepsy before its acquisition by UCB.
Broad incumbents
- Jazz Pharmaceuticals: Jazz is the parent of GW Pharmaceuticals after the $7.2B 2021 acquisition and the commercial distributor of Epidiolex. It is broadly comparable as the acquirer/owner of GW's CBD epilepsy franchise and operates an overlapping CNS/neuroscience portfolio including sleep and rare disease medicines.
- AbbVie / Allergan: AbbVie (post-Allergan acquisition) markets a deep CNS portfolio including therapies for neurological conditions and operates a global specialty neurology salesforce that overlaps with GW's distribution into neurology/epilepsy prescribers.
- Eisai Co., Ltd. Eisai is a major Japanese pharmaceutical company with a substantial neurology franchise including Fycompa (perampanel) for epilepsy. It is comparable as a broad incumbent operating in branded neurology/CNS prescription drugs overlapping with GW's epilepsy focus.
Emerging players
- Canopy Growth Corporation: Canopy Growth is a major cannabis company with pharmaceutical and medical-cannabis divisions aiming at prescription-grade cannabinoid therapies. It is comparable as an emerging player pursuing FDA-grade cannabinoid drug development adjacent to GW's established CBD pharmaceutical franchise.
- Tilray Brands: Tilray operates a pharmaceutical cannabis platform including GMP-cannabinoid production for clinical trials and prescription channels. It is comparable as an emerging cannabis pharma player pursuing regulated cannabinoid medicines in a manner adjacent to GW.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
GW Pharmaceuticals social profiles
Digital presenceGW Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
GW Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles7 records
GW Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds6 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GW Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GW Pharmaceuticals
What does GW Pharmaceuticals do?
GW Pharmaceuticals develops and commercializes FDA-approved prescription medications derived from cannabinoids, with its primary product being Epidiolex, a pharmaceutical-grade CBD oral solution approved for the treatment of severe forms of epilepsy including Dravet syndrome and Lennox-Gastaut syndrome. The company also maintained a research pipeline exploring novel cannabinoid therapeutics for additional indications such as opioid use disorder.
Is GW Pharmaceuticals a public or private company?
GW Pharmaceuticals is a private company. It is classified as corporate owned and is currently acquired.
When was GW Pharmaceuticals founded?
GW Pharmaceuticals was founded in 1998. It employs 1,001 to 5,000 people.
Where is GW Pharmaceuticals based?
GW Pharmaceuticals is headquartered in Histon, United Kingdom, in the Europe region.
How does GW Pharmaceuticals make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are GW Pharmaceuticals's main competitors?
Direct peers on record are Marinus Pharmaceuticals, UCB, Biohaven Pharmaceuticals, SK Life Science and Zogenix. Broad incumbents are Jazz Pharmaceuticals, AbbVie / Allergan and Eisai Co., Ltd.. Emerging players are Canopy Growth Corporation and Tilray Brands.
Does GW Pharmaceuticals have an API?
No public API is recorded for GW Pharmaceuticals.
What industry is GW Pharmaceuticals in?
GW Pharmaceuticals's product category is Cannabinoid Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.